Movement Alert｜Moderna, Inc. Rises 5.15% in Pre-Market Trading, First mRNA Flu Vaccine FDA Approval Continues to Boost Shares

Market Focus

Aug 10

On August 10, Moderna, Inc. rose 5.15% in pre-market trading, trading at $62.12/share, with turnover of $3.10 million. The stock continues to gain momentum following the FDA approval of the company's seasonal influenza vaccine mFLUSIVA.

The approval, announced earlier this month, marks a milestone as the first mRNA vaccine to enter the flu market and Moderna's fourth FDA-cleared product in the US. mFLUSIVA is approved for adults aged 50 and above, with the company expecting availability through select retail channels in the coming weeks to cover the 2026-2027 respiratory virus season. The vaccine is also currently under regulatory review in Australia, Canada, and Europe.

The approval came after an earlier regulatory setback, making it a significant commercial victory for Moderna. Previously, Bank of America adjusted its price target on Moderna to $38 from $34 while maintaining an Underperform rating, and the analyst consensus target stands at $50.53. Market confidence in Moderna's mRNA platform expansion and commercialization prospects continues to strengthen.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1168819953"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1168819953\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1168819953?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-10 16:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1168819953","market":"us","top_or_hot":-1,"title":"Movement Alert｜Moderna, Inc. Rises 5.15% in Pre-Market Trading, First mRNA Flu Vaccine FDA Approval Continues to Boost Shares","media":"Market Focus","content":"<p><p>On August 10, Moderna, Inc. rose 5.15% in pre-market trading, trading at $62.12/share, with turnover of $3.10 million. The stock continues to gain momentum following the FDA approval of the company's seasonal influenza vaccine mFLUSIVA.</p><p>The approval, announced earlier this month, marks a milestone as the first mRNA vaccine to enter the flu market and Moderna's fourth FDA-cleared product in the US. mFLUSIVA is approved for adults aged 50 and above, with the company expecting availability through select retail channels in the coming weeks to cover the 2026-2027 respiratory virus season. The vaccine is also currently under regulatory review in Australia, Canada, and Europe.</p><p>The approval came after an earlier regulatory setback, making it a significant commercial victory for Moderna. Previously, Bank of America adjusted its price target on Moderna to $38 from $34 while maintaining an Underperform rating, and the analyst consensus target stands at $50.53. Market confidence in Moderna's mRNA platform expansion and commercialization prospects continues to strengthen.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Moderna, Inc. Rises 5.15% in Pre-Market Trading, First mRNA Flu Vaccine FDA Approval Continues to Boost Shares</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Moderna, Inc. Rises 5.15% in Pre-Market Trading, First mRNA Flu Vaccine FDA Approval Continues to Boost Shares\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-10 16:53</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 10, Moderna, Inc. rose 5.15% in pre-market trading, trading at $62.12/share, with turnover of $3.10 million. The stock continues to gain momentum following the FDA approval of the company's seasonal influenza vaccine mFLUSIVA.</p><p>The approval, announced earlier this month, marks a milestone as the first mRNA vaccine to enter the flu market and Moderna's fourth FDA-cleared product in the US. mFLUSIVA is approved for adults aged 50 and above, with the company expecting availability through select retail channels in the coming weeks to cover the 2026-2027 respiratory virus season. The vaccine is also currently under regulatory review in Australia, Canada, and Europe.</p><p>The approval came after an earlier regulatory setback, making it a significant commercial victory for Moderna. Previously, Bank of America adjusted its price target on Moderna to $38 from $34 while maintaining an Underperform rating, and the analyst consensus target stands at $50.53. Market confidence in Moderna's mRNA platform expansion and commercialization prospects continues to strengthen.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MRNA","symbol_name":"Moderna, Inc.","start_time":0,"source_url":"","article_id":"1168819953","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1168819953","pubTimestamp":1786351990,"columns":[{"name":"Product Release","id":31,"label_key":"productRelease"}],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 10, Moderna, Inc. rose 5.15% in pre-market trading, trading at $62.12/share, with turnover of $3.10 million. The stock continues to gain momentum following the FDA approval of the company's...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MRNA":"Moderna, Inc."},"translate_title":"走势警报|Moderna, Inc. 盘前交易上涨 5.15%，FDA 批准首个 mRNA 流感疫苗继续提振股价","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRNA":1},"content_text":"On August 10, Moderna, Inc. rose 5.15% in pre-market trading, trading at $62.12/share, with turnover of $3.10 million. The stock continues to gain momentum following the FDA approval of the company's seasonal influenza vaccine mFLUSIVA.The approval, announced earlier this month, marks a milestone as the first mRNA vaccine to enter the flu market and Moderna's fourth FDA-cleared product in the US. mFLUSIVA is approved for adults aged 50 and above, with the company expecting availability through select retail channels in the coming weeks to cover the 2026-2027 respiratory virus season. The vaccine is also currently under regulatory review in Australia, Canada, and Europe.The approval came after an earlier regulatory setback, making it a significant commercial victory for Moderna. Previously, Bank of America adjusted its price target on Moderna to $38 from $34 while maintaining an Underperform rating, and the analyst consensus target stands at $50.53. Market confidence in Moderna's mRNA platform expansion and commercialization prospects continues to strengthen.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}